ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DEBIO 1453P

A development code. Also written as “Debio 1453P”.

Its studies are led by Debiopharm.

Furthest: phase 1, since Jun 16, 20251 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Debiopharm11 open or runningphase 1since Jun 16, 2025Jun 16, 2025Dec 2026phase 1 · NCT07035769

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT07035769 · 112 planned · Belgium

Ahead

  1. Dec 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07035769

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07035769Healthy Participants · Belgium1RecruitingDec 2026112

How it is read

Names in the registry

  • “Debio 1453P”, 1 entry

Codes read as this program: DEBIO1453P.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.